COVID-19与肝损伤患病率及相关因素的关系

IF 0.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Hepatitis Monthly Pub Date : 2021-12-21 DOI:10.5812/hepatmon.121160
H. Fallatah, Waleed S Al Ghamdi, Saad M Al Dosari, Abdullah H Jabbad, Majed Fagih, Hisham O Akbar
{"title":"COVID-19与肝损伤患病率及相关因素的关系","authors":"H. Fallatah, Waleed S Al Ghamdi, Saad M Al Dosari, Abdullah H Jabbad, Majed Fagih, Hisham O Akbar","doi":"10.5812/hepatmon.121160","DOIUrl":null,"url":null,"abstract":"Background: Novel Coronavirus Disease 19 (COVID-19) was reported by the WHO as a pandemic in March 2020. It was associated with liver injury in up to 50% of patients. This retrospective cohort study investigated the prevalence and associated factors of liver injury among COVID-19 patients. Methods: We include 2319 consecutive COVID-19 patients from April 2020 to November 2020. Liver function tests were performed at baseline, 24–48 h after admission, and before mortality/discharge. We compared Saudis and non-Saudis, in admission rate, serum ALT level, morbidity, and mortality. Serum ALT was compared between sexes, admitted and non-admitted patients, and the deceased and survivors. Results: Men (1356; 58.5%) and non-Saudis (1328; 57.3%) were predominant. The mean (SD) age was 41.67 ± 18.3 years (18 - 100). One-third of the patients had comorbidities, and 1022 (44.1%) required hospital admission. Intensive Care Unit (ICU) transfer was required in 185/1022 (18%). Male and non-Saudis were most likely to be transferred to the ICU (P < 0.001). Hepatocellular liver injury was found in 797 (34.4%) patients. Male and admitted patients were more likely to have a hepatic injury (P = 0.001). Conclusions: The mortality rate among admitted patients was 17.8% (182/1022). Mortality was associated with older age and hepatic injury (P < 0.001 and P = 0.004, respectively).","PeriodicalId":12895,"journal":{"name":"Hepatitis Monthly","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of COVID-19 with Hepatic Injury Prevalence and Associated Factors\",\"authors\":\"H. Fallatah, Waleed S Al Ghamdi, Saad M Al Dosari, Abdullah H Jabbad, Majed Fagih, Hisham O Akbar\",\"doi\":\"10.5812/hepatmon.121160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Novel Coronavirus Disease 19 (COVID-19) was reported by the WHO as a pandemic in March 2020. It was associated with liver injury in up to 50% of patients. This retrospective cohort study investigated the prevalence and associated factors of liver injury among COVID-19 patients. Methods: We include 2319 consecutive COVID-19 patients from April 2020 to November 2020. Liver function tests were performed at baseline, 24–48 h after admission, and before mortality/discharge. We compared Saudis and non-Saudis, in admission rate, serum ALT level, morbidity, and mortality. Serum ALT was compared between sexes, admitted and non-admitted patients, and the deceased and survivors. Results: Men (1356; 58.5%) and non-Saudis (1328; 57.3%) were predominant. The mean (SD) age was 41.67 ± 18.3 years (18 - 100). One-third of the patients had comorbidities, and 1022 (44.1%) required hospital admission. Intensive Care Unit (ICU) transfer was required in 185/1022 (18%). Male and non-Saudis were most likely to be transferred to the ICU (P < 0.001). Hepatocellular liver injury was found in 797 (34.4%) patients. Male and admitted patients were more likely to have a hepatic injury (P = 0.001). Conclusions: The mortality rate among admitted patients was 17.8% (182/1022). Mortality was associated with older age and hepatic injury (P < 0.001 and P = 0.004, respectively).\",\"PeriodicalId\":12895,\"journal\":{\"name\":\"Hepatitis Monthly\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatitis Monthly\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5812/hepatmon.121160\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatitis Monthly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/hepatmon.121160","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:新型冠状病毒病19 (COVID-19)于2020年3月被世卫组织报告为大流行。在高达50%的患者中,它与肝损伤有关。本回顾性队列研究调查了COVID-19患者肝损伤的患病率及相关因素。方法:纳入2020年4月至2020年11月连续2319例COVID-19患者。在基线、入院后24-48小时和死亡/出院前进行肝功能检查。我们比较了沙特人和非沙特人的入院率、血清ALT水平、发病率和死亡率。血清ALT在性别、住院和非住院患者、死者和幸存者之间进行比较。结果:男性1356人;58.5%)和非沙特人(1328人;57.3%)为主。平均(SD)年龄为41.67±18.3岁(18 ~ 100岁)。三分之一的患者有合并症,1022例(44.1%)需要住院治疗。185/1022(18%)患者需要转重症监护病房(ICU)。男性和非沙特人最有可能转至ICU (P < 0.001)。肝细胞性肝损伤797例(34.4%)。男性和住院患者更容易发生肝损伤(P = 0.001)。结论:住院患者死亡率为17.8%(182/1022)。死亡率与年龄和肝损伤相关(P分别< 0.001和P = 0.004)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Association of COVID-19 with Hepatic Injury Prevalence and Associated Factors
Background: Novel Coronavirus Disease 19 (COVID-19) was reported by the WHO as a pandemic in March 2020. It was associated with liver injury in up to 50% of patients. This retrospective cohort study investigated the prevalence and associated factors of liver injury among COVID-19 patients. Methods: We include 2319 consecutive COVID-19 patients from April 2020 to November 2020. Liver function tests were performed at baseline, 24–48 h after admission, and before mortality/discharge. We compared Saudis and non-Saudis, in admission rate, serum ALT level, morbidity, and mortality. Serum ALT was compared between sexes, admitted and non-admitted patients, and the deceased and survivors. Results: Men (1356; 58.5%) and non-Saudis (1328; 57.3%) were predominant. The mean (SD) age was 41.67 ± 18.3 years (18 - 100). One-third of the patients had comorbidities, and 1022 (44.1%) required hospital admission. Intensive Care Unit (ICU) transfer was required in 185/1022 (18%). Male and non-Saudis were most likely to be transferred to the ICU (P < 0.001). Hepatocellular liver injury was found in 797 (34.4%) patients. Male and admitted patients were more likely to have a hepatic injury (P = 0.001). Conclusions: The mortality rate among admitted patients was 17.8% (182/1022). Mortality was associated with older age and hepatic injury (P < 0.001 and P = 0.004, respectively).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepatitis Monthly
Hepatitis Monthly 医学-胃肠肝病学
CiteScore
1.50
自引率
0.00%
发文量
31
审稿时长
3 months
期刊介绍: Hepatitis Monthly is a clinical journal which is informative to all practitioners like gastroenterologists, hepatologists and infectious disease specialists and internists. This authoritative clinical journal was founded by Professor Seyed-Moayed Alavian in 2002. The Journal context is devoted to the particular compilation of the latest worldwide and interdisciplinary approach and findings including original manuscripts, meta-analyses and reviews, health economic papers, debates and consensus statements of the clinical relevance of hepatological field especially liver diseases. In addition, consensus evidential reports not only highlight the new observations, original research, and results accompanied by innovative treatments and all the other relevant topics but also include highlighting disease mechanisms or important clinical observations and letters on articles published in the journal.
期刊最新文献
Hepatitis A Chronic Immunity in Iran: A Geographic Information System-Based Study Salvage Treatment of Nivolumab and Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma Aspartate Aminotransferase to Platelet Ratio Index Before and After the Treatment of Chronic Hepatitis C Patients with Sofosbuvir/Daclatasvir Pretreatment of Exosomes Derived from hUCMSCs with LPS Ameliorates Liver Fibrosis by Inhibiting the Smad3C Through Upregulating MiR-126 in the HSC-T6 Cell Line Effect of Complementary Therapy with Hydro-Ethanolic Extract of Aerial Parts of Portulaca oleracea on Clinical and Paraclinical Findings in Patients with Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial Protocol
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1